Overview

This trial is active, not recruiting.

Condition peripheral arterial occlusive disease
Treatment pad endovascular treatments
Sponsor Cardiovascular Systems Inc
Start date May 2013
End date December 2020
Trial size 1204 participants
Trial identifier NCT01855412, CLN-0001-P

Summary

The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
pad endovascular treatments
All FDA-cleared endovascular PAD treatments
Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
pad endovascular treatments
All FDA-cleared endovascular PAD treatments
Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
pad endovascular treatments
All FDA-cleared endovascular PAD treatments

Primary Outcomes

Measure
Procedural success of Endovascular PAD Treatment(s)
time frame: After the last subject's 5-year follow-up visit

Secondary Outcomes

Measure
Lesion Success of Endovascular PAD Treatment(s)
time frame: After the last subject's 5-year follow-up visit

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Subject's age ≥ 18 years. 2. Subject presents with a Rutherford classification of 2 to 6. 3. Subject presents with clinical evidence of PAD requiring endovascular intervention on one or both limbs that includes a target lesion in a native vessel located within or extending into 10 cm above the medial epicondyle to the digital arteries. - If subject presents with bilateral disease, the first limb treated with a lesion in the target area will be considered the target limb. - For subjects with one or more wounds on the target limb, the target lesion(s) should be considered the lesion(s) in the vessel(s) that provide(s) blood flow to the wound(s). 4. Subject has at least one lesion in a native vessel located within or extending into the target area that is crossed and treated with an endovascular device. Exclusion Criteria: 1. Subject is unwilling or unable to sign the IRB-approved informed consent form (ICF). 2. Subject is unable to understand or comply with the study protocol requirements. 3. Subject is currently participating in an investigational drug or other device study that can clinically interfere with the endpoints of this study. 4. Subject requires a conversion from endovascular intervention to a surgical bypass graft for any lesion(s) in the target area, as determined by the Investigator. 5. Subject has an in-stent restenosis in the target area, and this lesion is the only one requiring treatment. 6. Subject is pregnant or planning to become pregnant within the study period. 7. Subject has an anticipated life span of less than one (1) year.

Additional Information

Official title LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD)
Principal investigator William Gray, MD
Description This is a prospective, observational, multi-center, clinical study examining predictors of clinical outcomes for patients undergoing endovascular treatment of lesions within or extending into the target area (10 cm above the medial epicondyle to the digital arteries). This includes disease in a vessel located within or extending into the distal superficial femoral artery (SFA), popliteal (POP), tibial peroneal trunk (TPT), anterior tibial (AT), posterior tibial (PT), and peroneal tibial (PR) arteries.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Cardiovascular Systems Inc.